JournalArta
Saturday, November 21, 2026 · JakartaS&P 7,028.75 ▼2.05%USD/IDR 18,279 ▲0.12%
JournalArta
Global Edition
beyond headlines
Advertisement

Daraxonrasib trial finds no detectable tumors in 8.2%

A small clinical trial found no detectable tumors in 8.2% of patients who received daraxonrasib with chemotherapy for advanced pancreatic cancer. Researchers reported longer-term follow-up is needed, while a cancer charity said more trials must precede an assessment of the treatment for NHS use.

By matthew jonathan
WIB2 min read
Daraxonrasib trial finds no detectable tumors in 8.2%
Daraxonrasib trial finds no detectable tumors in 8.2%

Daraxonrasib combined with chemotherapy left no detectable tumors in 8.2% of patients with advanced pancreatic cancer, according to a clinical trial. The findings came from a study of 61 patients and a typical follow-up of 18 months.

The drug is a once-daily pill. Tumors shrank or disappeared in 60.7% of patients who received it with chemotherapy.

Researchers presented the phase one/two findings at the European Organisation for Research and Treatment of Cancer in Barcelona. Longer-term survival data will come as the trial progresses.

Trial measures survival and tumor growth

One year after treatment, 76.6% of patients were alive. That compares with around 40 to 45% of patients given chemotherapy alone.

Advertisement

Tumors stopped growing in 90.2% of the 61 patients over a typical period of 18 months. Across the group, tumors took an average of 12.8 months to return or start growing again.

Dr. Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Centre in New York, presented the findings. He called the results “a massive, massive breakthrough” in treating pancreatic cancer.

Asked whether patients whose tumors were no longer detectable were cured, Park said: “This is the closest to cure.”

Cancer frequently develops resistance to drug treatment, Park said. He said the combination aims to delay that resistance.

Daraxonrasib targets the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumors. The gene continuously signals cancer cells to grow.

Advertisement

Earlier findings showed the drug almost doubled survival time compared with chemotherapy alone in patients with aggressive, advanced pancreatic cancer. It also caused fewer side effects.

Researchers call for more trials

Dr. Madina Kara, head of research at Pancreatic Cancer UK, called the findings encouraging while describing the study as small and initial. She said the results showed the drug and chemotherapy could be effective together.

Kara said half of people with pancreatic cancer die within three months of diagnosis. More than 11,000 people are diagnosed with the disease each year in the UK, and more than 10,000 die from it.

She called on the UK Government to increase investment in pancreatic research and clinical trials. She also sought a rapid pathway to deliver new treatments once they are proven to work.

Advertisement

Cancer Research UK chief executive Michelle Mitchell said more trials are needed before the treatment can be assessed for NHS use. She also called for research into how the drug could be used alongside other therapies.

The final phase-three study has enough patients in the US, although some sites in Europe may have space.

Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Stock Market Today: Dow Slides 1.34% and VIX Jumps 15% at MiddayStock Market Today: Dow Slides 1.34% and VIX Jumps 15% at Midday
  2. 2Joachim Klement to Sell Stocks After S&P 500 SignalJoachim Klement to Sell Stocks After S&P 500 Signal
  3. 3Kenneth Walker’s Groin Injury Puts Cardinals Game in DoubtKenneth Walker’s Groin Injury Puts Cardinals Game in Doubt
  4. 4Stock Market Today: Nasdaq, S&P 500 Futures Slide as AI Selloff DeepensStock Market Today: Nasdaq, S&P 500 Futures Slide as AI Selloff Deepens
  5. 5Pat Cummins Faces Captaincy Doubts From Mitchell JohnsonPat Cummins Faces Captaincy Doubts From Mitchell Johnson
Advertisement
Don't Miss

Latest News

All stories →
  1. Trump’s Proposed Arch Draws Opposition From Fallen Marines’ FamiliesWorld · United StatesTrump’s Proposed Arch Draws Opposition From Fallen Marines’ FamiliesNov 21
  2. Trump Tells European Leaders Putin Wants Ukraine War DealWorld · United StatesTrump Tells European Leaders Putin Wants Ukraine War DealNov 21
  3. Iraqi Forces Enter Kataib Hezbollah Stronghold Under DealWorld · Middle EastIraqi Forces Enter Kataib Hezbollah Stronghold Under DealNov 21
  4. NFL Week 11 Picks: 49ers Favored Over Vikings in MexicoSport · More SportsNFL Week 11 Picks: 49ers Favored Over Vikings in MexicoNov 21
  5. Advertisement
  6. India A Bowl Nepal Out for 26 in 306-Run WinSport · More SportsIndia A Bowl Nepal Out for 26 in 306-Run WinNov 21
  7. UK and EU Agree Trade and Youth Travel DealsWorld · EuropeUK and EU Agree Trade and Youth Travel DealsNov 21
  8. Dark Energy May Stem From Strong Force, Researchers SayTechnologyDark Energy May Stem From Strong Force, Researchers SayNov 21
  9. Poland Says Russian Missiles Crashed During Allied DrillsWorld · EuropePoland Says Russian Missiles Crashed During Allied DrillsNov 21